{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-000247","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.332589+00:00","generated_at":"2026-06-07T05:04:37.973743+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Court finds Teva does not infringe Corcept's Korlym patents; Corcept plans appeal","bullets":["District of New Jersey ruled Teva does not infringe Corcept's U.S. Patents 10,195,214 and 10,842,800.","Patents cover methods of safely administering Korlym with strong CYP3A4 inhibitors.","CEO Joseph Belanoff called decision disappointing and based on legal and factual errors.","Corcept will pursue a vigorous appeal; believes patents expanded treatment options for Cushing's syndrome.","FDA had added the patented methods to Korlym's prescribing instructions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-000247","json":"https://secwatch.observer/filing/0001193125-24-000247.json","markdown":"https://secwatch.observer/filing/0001193125-24-000247.md","text":"https://secwatch.observer/filing/0001193125-24-000247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312524000247/0001193125-24-000247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312524000247/d676865d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:04:37.973743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}